Cellectis CLLS
NASDAQ CLLS
$3.24 -0.08 (-2.41%)
At close: Sep 4, 2026 · 4:00 PM EDT

Cellectis (CLLS) Non Operating Income (2021 - 2022)

Cellectis (CLLS) posted quarterly Non Operating Income of -$7.4 million for Q1 2026, down 88.68% year-over-year from -$65.8 million in Q1 2025, and down 143.52% quarter-over-quarter from $17.1 million in Q4 2025.

Analysis

Cellectis (CLLS) Non Operating Income (2021 - 2022) Analysis & Trends

Cellectis' Non Operating Income history runs 12 years deep, the most recent figure standing at -$7.4 million for Q1 2026.

  • In Q1 2026, Non Operating Income fell 88.68% year-over-year to -$7.4 million; the TTM figure through Mar 2026 stood at -$11.9 million (down 60.65% YoY), while the FY2025 annual figure was -$34.9 million, down 253.29% from the prior year.
  • Non Operating Income for Q1 2026 stood at -$7.4 million, down from $17.1 million in the prior quarter.
  • The five-year high for Non Operating Income was $17.1 million in Q4 2024, with the low at -$26.3 million in Q1 2024.
  • The 5-year median for Non Operating Income is -$5.8 million (2023), against an average of -$5.3 million.
  • Peak annual rise in Non Operating Income reached 301.04% in 2022, while the deepest fall reached 737.74% in 2022.
  • Cellectis' Non Operating Income stood at -$20.0 million in 2022, then plunged by 30.87% to -$26.1 million in 2023, then surged by 165.54% to $17.1 million in 2024, then changed by 0.0% to $17.1 million in 2025, then slumped by 143.52% to -$7.4 million in 2026.
  • Business Quant data shows CLLS's Non Operating Income at -$7.4 million in Q1 2026, $17.1 million in Q4 2025, and -$7.5 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 234.30 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -139.24 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -53.64 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -51.63 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Cellectis 321.90 Mn 155.05 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 483,000.00
Dec 31, 2021 8,000.00